We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 19, 2021

Dose Escalation of Subcutaneous Epcoritamab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

The Lancet


Additional Info

The Lancet
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Lancet 2021 Sep 08;[EPub Ahead of Print], M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, MED Chamuleau, DJ Lewis, A Sureda Balari, D Cunningham, RS Oliveri, B Elliott, D DeMarco, A Azaryan, C Chiu, T Li, KM Chen, T Ahmadi, PJ Lugtenburg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading